Waters Corporation Website

Waters Corporation

NYSE-WAT

Company Overview

Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by life science, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.

  • Name

    Waters Corporation

  • CEO

    Udit Batra

  • Website

    www.waters.com

  • Sector

    Life Sciences Tools and Services

  • Year Founded

    1958

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Bulls Say

  • Waters' analytical instruments remain the gold standard in several applications, especially LC-MS for biopharmaceutical firms, where regulations preserve consistent recurring sales for many years.

  • Historically, Waters has maintained a disciplined capital allocation strategy that has preserved returns on invested capital near the top of the industry, and even after the planned BD merger, ROICs look likely to remain solid.

  • Waters continues to benefit from expanding branded and generic biopharmaceuticals and the increase in food safety and environmental testing by various entities.

Bears Say

  • With the pending BD merger, Waters could run into integration issues and other challenges while transitioning from a very focused firm to a more diverse one.

  • Competition from the likes of Agilent, Merck KGaA, and Thermo Fisher, among others, puts consistent pressure on Waters to innovate.

  • The post-pandemic reset period has created questions around the ongoing growth trajectory for life science tools like the ones Waters sells.

Source: Morningstar Analysis - Nov 04, 2025

What's happening

Nov 6, 2025 - Dec 6, 2025

Waters Corporation Sees Significant Stock Surge Amid Strategic Developments

  • Morgan Stanley initiates coverage on Waters Corp with an Equalweight rating and a price target of $423.00.
  • CEO Udit Batra's participation in the Jefferies Global Healthcare Conference highlights innovative advancements, including the Charged Aerosol Detector (CAD).
  • Regulatory approval for acquiring Becton Dickinson’s biosciences business paves the way for market expansion.

Over the past month, Waters Corporation (WAT) experienced a notable increase of 6.0% in its stock price. This performance significantly outpaced the S&P 500's return of 1.2%, resulting in an overperformance of 4.8% relative to the index. The rise was largely driven by key events that enhanced investor sentiment towards WAT shares.

A major catalyst was Morgan Stanley's initiation of coverage on WAT with an Equalweight rating and a price target set at $423.00, shortly after shares closed at $403.42. Additionally, Waters made headlines by announcing its participation in the Jefferies Global Healthcare Conference where CEO Udit Batra would discuss future strategies and innovations within the company, generating excitement among investors regarding their commitment to advancing healthcare solutions through products like their newly launched Charged Aerosol Detector (CAD). The CAD aims to enhance lab productivity while addressing communication errors common in multi-vendor configurations.

Another significant milestone during this period was regulatory approval from the European Commission for Waters' proposed acquisition of Becton Dickinson’s biosciences and diagnostic solutions businesses. This approval is expected to facilitate expansion into new markets and strengthen Waters’ capabilities within diagnostics—an area poised for growth.

Despite these positive developments, some bearish sentiments emerged as analysts adjusted their price targets for WAT stock; while firms like TD Cowen raised their targets significantly, others maintained Hold ratings which tempered overall enthusiasm slightly. Overall, WAT not only demonstrated strong performance relative to broader market indices but also outperformed its sector peers within Health Care (XLV), exceeding sector performance by 0.8%.

NYSE:WAT